Paul S. Aisen

This clinical trial aims to test whether new drugs that target tau protein in the brain can slow Alzheimer's disease progression, either alone or combined with existing amyloid-targeting treatments. It will enroll 750 adults aged 50-80 who have early signs of Alzheimer's but mini…

This study is testing a vaccine called AADvac1, designed to target a harmful protein called tau in the brain. It aims to see if the vaccine, given alone or with another Alzheimer's drug, can reduce tau buildup and slow disease progression in adults aged 50-80 with very early sign…